ArticleJACC. Case reports2026
Unmasking Essential Thrombocythemia in Heparin-Induced Thrombocytopenia After Coronary Artery Bypass Grafting.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Coronary Thrombosis Outpaces Technical Success.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeparin-induced thrombocytopenia (HIT) and JAK2 V617F-positive essential thrombocythemia (ET) are prothrombotic conditions that complicate postoperative management. CASE SUMMARY: A 68-year-old man underwent coronary artery bypass grafting (CABG) and developed recurrent arterial thrombosis with an abrupt platelet decline prompting evaluation for HIT. Platelet factor 4/heparin immunoassays were positive, whereas serotonin release assays remained negative during potent P2Y DISCUSSION: Unexplained persistent thrombocytosis in the setting of prior arterial thrombosis should raise suspicion for an underlying myeloproliferative neoplasm. Moreover, the coexistence of JAK2 V617F-positive ET and probable HIT following CABG confers a heightened thrombotic risk and underscores the diagnostic challenges associated with functional HIT assays in the context of potent P2Y TAKE-HOME MESSAGE: Persistent unexplained thrombocytosis with prior arterial thrombosis should raise suspicion for an occult myeloproliferative neoplasm, whereas postoperative HIT remains a clinical consideration despite negative functional assays, particularly in the context of potent P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.